Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
US |
C
|
Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
|
1.1m USD | 0.5 | |
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -5 459 134.4 | |
US |
Eli Lilly and Co
NYSE:LLY
|
737.5B USD | 58.8 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 34 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 3 846.3 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
368.4B USD | 11.8 | ||
US |
Merck & Co Inc
NYSE:MRK
|
332.1B USD | 35.8 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
187.6B GBP | 174.5 | ||
CH |
Roche Holding AG
SIX:ROG
|
188.4B CHF | 9.3 | ||
CH |
Novartis AG
SIX:NOVN
|
181.2B CHF | 8.7 | ||
US |
Pfizer Inc
NYSE:PFE
|
162.7B USD | 13 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.